$20.20+0.7%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Company outlook: revenue of $2.7B to $2.7B for Fiscal year 2026 — down 1.7% on a year earlier ($2.7B)
Just reported
From Fortrea Holdings Inc.'s results release of October 29, 2026; its quarterly report has since been filed.
Actual
$691.5M
-1.4% y/y
+2.0% q/q
Guided
—
No guide given
Actual
$0.01
Guided
—
No guide given
Actual
$15M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $691.5M | $701.3M | -1.40% |
| Profit | $600K | -$15.9M | +103.77% |
| Profit per share | $0.01 | -$0.17 | +105.88% |
| Free Cash Flow | $52.5M | $79.5M | -33.96% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Fortrea Holdings Inc. has no earnings call transcript available.
“Fortrea delivered another quarter of progress on our return-to-growth strategy, reflecting stronger commercial execution, continued operational improvements and financial discipline,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services, delivered in highly flexible models that include full service, functional service provider and hybrid service structures. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, technology innovation and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Fortrea Holdings Inc.’s Item 2.02 8-K filed October 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.